癌症
癌症研究
生物
肿瘤进展
癌变
乳腺癌
癌基因
免疫疗法
生物标志物
DNA甲基化
肿瘤科
医学
基因
基因表达
细胞周期
遗传学
作者
Ye Hu,Nina Jiang,Xueqing Wang,Xiao Yu Wu,Bo Jiang,Yining Chen,Yiyan Zeng,Xiaofan Wei,Hongquan Zhang,Man Li
出处
期刊:Life Sciences
[Elsevier]
日期:2024-02-01
卷期号:338: 122389-122389
标识
DOI:10.1016/j.lfs.2023.122389
摘要
Cancer remains a significant global public health issue. There is growing proof that Ring Finger Protein 186 (RNF186) may play a function in pan-cancer, however, this has not yet been thoroughly determined. This study aims to analyze RNF186 with potential implications in progression and prognosis in human cancer.A comprehensive bioinformatics approaches combined with experimental verification were used across 33 types of cancers in this study to conduct a pan-cancer investigation of RNF186 from the perspectives of gene expression, prognosis, genomic alterations, immunological markers, gene set, and function.RNF186 is a valuable prognostic biomarker in several cancer types, especially breast invasive carcinoma (BRCA) and uterine corpus endometrial carcinoma (UCEC). The levels of RNF186 promoter methylation and genetic alterations may be responsible for some cancers' abnormal expression. Furthermore, RNF186 expression was determined to be associated with immune checkpoint genes. Analysis of RNF186-related genes revealed that proteasome and PI3K-AKT signaling pathway were primarily involved in the cellular function of RNF186. Additionally, our research first confirmed that RNF186 may function as an oncogene and contribute to cancer proliferation, migration and invasion in UCEC. In contrast, RNF186 may play an inhibitory role in BRCA progression. This function depends on the ligase activity of RNF186.This study suggests that RNF186 is a novel critical target for tumor progression in BRCA and UCEC. It reveals that RNF186 may be associated with tumor immunotherapy, which may provide an effective predictive evaluation of the prognosis of immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI